Age-Related Macular Degeneration

Air pollution is a health hazard, and not only for the lungs.

Although COVID-19 triggered widespread disruption in medical care across all specialties, ophthalmologists had to overcome unique challenges. In an interview with Healio, Rishi P. Singh, MD, discussed problems posed early in the pandemic, the benefits of telemedicine, caring for vulnerable populations in the COVID-19 era and the need for more advanced technology moving forward.

The best source of evidence to base one’s clinical decisions on is a well-designed prospective randomized masked controlled clinical trial.

Patients with age-related macular degeneration who are undergoing cataract surgery should be seen within 4 weeks after surgery and appropriately treated within 14 days if required.

Due to the COVID-19 pandemic, 2020 was marked by innovation and rapid advances in medicine, and the field of ophthalmology was no exception. With the unveiling of important data on age-related macular degeneration at the year’s major conferences, physicians may soon see these changes reflected in clinical practice.

The results of the 2020 Global Trends in Retina Survey reveal a world that is more interconnected and where interactions between groups and individuals in the ophthalmology community increasingly grow across global borders.

In this video, Chris Simms, vice president and U.S. franchise head of ophthalmics, and Lykke Hinsch Gylvin, MD, vice president and global medical franchise head at Novartis, discuss the latest news in their ophthalmology portfolio.

A majority of patients with age-related macular degeneration treated with investigational gene therapy GT005 experienced increases in complement factor I levels in an ongoing phase 1/2 clinical trial.

In this video, Caroline R. Baumal, MD, professor at Tufts University School of Medicine, discusses topics in age-related macular degeneration from the virtual American Academy of Ophthalmology annual meeting and her hopes for 2021.

Artificial intelligence-based telemedicine platform may allow for large-scale screening of patients with age-related macular degeneration while lowering the cost of care, according to a poster at AAO Annual Meeting.